€0.70
0.00%
Xetra, Fri, Jun 28 2024
ISIN
DE000A3H2184
Symbol
ECX
Index
Sector
Industry

Epigenomics Share price

€0.70
-0.98 58.21% 1M
-1.20 63.16% 6M
-1.19 62.96% YTD
-6.86 90.74% 1Y
-24.10 97.18% 3Y
-268.10 99.74% 5Y
-494.35 99.86% 10Y
Xetra, Closing price Fri, Jun 28 2024
ISIN
DE000A3H2184
Symbol
ECX
Index
Sector
Industry

Key figures

Market capitalization €20.00k
Enterprise Value €-3.20m
PER (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.25
EV/Sales (TTM) EV/Sales -7.11
P/S ratio (TTM) P/S ratio 0.04
P/B ratio (TTM) P/B ratio 0.31
Sales growth (TTM) Sales growth -92.80%
Turnover (TTM) Turnover €450.00k
EBIT (operating result TTM) EBIT €-14.68m
Free cash flow (TTM) Free cash flow €-12.98m
Cash position €3.58m
EPS (TTM) EPS €-19.49
P/E ratio expected negative
P/S ratio expected 0.07
EV/Sales expected negative
Show more

Is Epigenomics a top scorer stock according to the dividend, high growth investing or Leverman strategy?

As a free StocksGuide basic user, you can view the scores for all 6,953 shares worldwide.

Epigenomics Share analysis

Unlock scores for free

Analyst opinions

1 Analyst has issued a forecast Epigenomics:

1x Buy
100%

Analyst opinions

1 Analyst has issued a forecast Epigenomics:

Buy
100%

Financial data from Epigenomics

Profit and loss account P&L | Balance sheet | Cash flow


Quarter TTM Annually
Jun '23
+/-
%
0.45 0.45
93% 93%
100%
- Direct costs 2.33 2.33
276% 276%
518%
-1.88 -1.88
134% 134%
-418%
- Selling and administrative expenses 5.54 5.54
24% 24%
1,231%
- Research and development costs 5.03 5.03
10% 10%
1,118%
-12 -12
100% 100%
-2,767%
- Depreciation and amortization 2.23 2.23
374% 374%
496%
EBIT (operating result) EBIT -15 -15
119% 119%
-3,262%
Net profit -16 -16
470% 470%
-3,620%

Figures in millions EUR.

Don't miss a thing! We will send you all news about the Epigenomics share directly to your mailbox free of charge.

If you wish, you can receive an e-mail every morning in time for breakfast containing all the stock news relevant to you.

Epigenomics Share News

EQS
more than one year ago
Berlin (Deutschland), 23. Dezember 2022 – Die Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY; das "Unternehmen") gibt bekannt, dass Pareto Securities AS einen aktualisierten Research-Report veröffentlicht hat, in dem die Aktie der Epigenomics AG hochgestuft und eine Kaufempfehlung au...
EQS
more than one year ago
Für das Gesamtjahr 2022 erwartet der Vorstand nunmehr ein adjustiertes EBITDA (vor anteilsbasierter Vergütung) innerhalb der Bandbreite von EUR -10,2 Mio. bis EUR -10,8 Mio. und einen Finanzmittelverbrauch innerhalb der Bandbreite von EUR -13,5 Mio. bis EUR -14,0 Mio. Bislang war das Unternehmen ...
EQS
more than one year ago
Diese Veröffentlichung enthält ausdrücklich oder implizit in die Zukunft gerichtete Aussagen, die die Epigenomics AG und deren Geschäftstätigkeit betreffen. Diese Aussagen beinhalten bestimmte bekannte und unbekannte Risiken, Unsicherheiten und andere Faktoren, die dazu führen können, dass die ta...
More Epigenomics News

Company profile

Epigenomics AG is a molecular diagnostics company, which engages in the development and commercializing of proprietary products for the screening and diagnosis of cancer. It offers Epi proColon, a blood-based test for the early detection of colorectal cancer; Epi proLung, a confirmatory test that aids in the diagnosis of lung cancer, Epi BiSKit, a kit for the preparation of purified, bisulfite-converted DNA and, HCCBloodTest, a blood test for cirrhotic patients at high-risk for the development of hepatocellular carcinoma. The comapny was founded by Oliver Schacht, Christian Piepenbrock, Kurt Berlin, Jörn Walter, and Ivo Gut on April 30, 1997 and is headquartered in Berlin, Germany.

Head office Germany
CEO Gregory Hamilton
Employees 34
Founded 1997
Website www.epigenomics.com

Register for free

StocksGuide is the tool for easily finding, analyzing and monitoring shares. Learn from successful investors and make well-founded investment decisions. We make you a self-determined investor.

The Apple share at a glance with charts, current key figures, news and share analyses.
The best dividend stocks in the dividend top scorer list.
Stock analyses of the best stocks worldwide.
Build wealth now